August 2012
-
The US FDA has announced a December 12 meeting of the Psychopharmacologic Drugs Advisory Committee to discuss safety concerns related to Alexza’s Adasuve loxapine inhalation powder for the treatment of agitation associated with schizophrenia or… Read more . . .
-
Day 2 of DDL 22 started off with a focus on delivery devices, beginning with a talk by Professor Myrna Dolovich of McMaster University on selecting the correct device for patients and ending with a… Read more . . .
-
The United States Patent and Trademark Office has issued US Patent No. 8,071,127 regarding formulations of inhaled liposomal and free ciprofloxacin to Aradigm Corporation. The patent covers the company’s lead candidate, Pulmaquin dual release ciprofloxacin… Read more . . .
-
A report from research firm Decision Resources predicts no growth in the asthma drug market through 2020, in large part due to incursions by generics and greater competition. According to the company, “The overall asthma… Read more . . .
-
Merck and NanoBio will conduct preclinical studies to evaluate a vaccine combining Merck’s respiratory syncyctial virus (RSV) antigen with NanoBio’s NanoStat adjuvant. NanoBio has already conducted studies that showed the induction of immunity by a… Read more . . .
-
The prize for the best poster presented at PowderFlow 2011 was awarded to Hanne Kinnunen, a PhD student in the Pharmaceutical Surface Science Research Group, Department of Pharmacy and Pharmacology at the University of Bath,… Read more . . .
-
Aptar Pharma launched its new DF30Plus metering valve, an extension of its DF30 line, at DDL 22. According to the company, the new valve is more compatible with a wide range of formulations, including those… Read more . . .
-
Nearly 500 people attended the first day of the 2011 Drug Delivery to the Lungs meeting (DDL 22) at the Edinburgh International Conference Centre. Approximately 50 of the DDL 22 attendees were also registered for… Read more . . .
-
Pearl Therapeutics has announced positive top-line results from a Phase 2b dose-ranging study of its PT001 glycopyrrolate (GP) MDI in patients with moderate-to-severe COPD. The randomized, double-blind study compared 4 doses of the PT001 MDI… Read more . . .
-
Swedish pharma company Meda released a statement regarding a new patent for its Astepro nasal spray that reads in its entirety: “The United States Patent and Trademark Office (USPTO) today issued a patent related to… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland